Receptor-mediated regulation of prolactin synthesis by 1,25-dihydroxycholecalciferol (1,25(OH)2D3) in the pituitary cell strain GH4C1 is dependent on the concentration of extracellular calcium. We have now investigated the actions of 1,25(OH)2D3 on cytosolic free calcium concentrations [( Ca2+]i) in these cells using the fluorescent indicator quin2. Basal resting [Ca2+]i was unchanged in cells treated with 1 nM 1,25(OH)2D3 either acutely (from 0 to 15 min) or for periods of up to 48 h. However, the initial peak of the biphasic change in [Ca2+]i induced by thyrotropin-releasing hormone (TRH) was enhanced more than twofold in cells pretreated for 24 or 48 h with 1,25(OH)2D3. This 1,25(OH)2D3-enhanced calcium response was restricted to the initial phase of TRH action; the secondary plateau phase was unaffected. Neither the affinity nor number of TRH receptors nor the early time course of [3H]MeTRH binding to GH4C1 cells were affected by pretreatment with 1,25(OH)2D3. Because TRH binding was not altered, four sites along the intracellular signal transduction pathway of TRH action were examined. Neither protein kinase C activation nor inositol polyphosphate accumulation were enhanced in response to TRH, in 1,25(OH)2D3 pretreated cells, indicating that phosphatidylinositol hydrolysis was unchanged by pretreatment. A low concentration of ionomycin was used to probe the size of the nonmitochondrial intracellular calcium pool that is sensitive to TRH. Ionomycin was not able to mobilize […] 
, and these increases have been investigated in detail using the growth hormone (GH) clonal rat pituitary cell strains (6) (7) (8) . These cells also display receptor-mediated responses to the calcium mobilizing steroid hormone 1,25(OH)2D3 (9, 10) . Thus, GH4C, cells represent a nonclassical target cell model for this hormone. Treatment of GH4C1 cells with low concentrations of 1,25(OH)2D3 in hormone-free, chemically defined medium induces increases in prolactin (PRL) synthesis (9) . The effects of the steroid are specific to PRL, with no increase in growth hormone production. Furthermore, these responses are dependent upon calcium, as determined by changing the extracellular concentration of this ion (9, 10) . 1,25(0H)2D3 has long been known to increase calcium transport across gut epithelium, in the distal renal tubule and in bone, although the mechanism underlying this transport remains unknown (1 1, 12) . Because (4, 5) . The initial rapid peak (phase I) occurs within the first minute after addition of TRH. When cells are grown in serum-free medium containing 400 gM calcium, TRH increases [Ca21], levels -2.6-fold above basal levels. The majority ofthe calcium comprising this peak (-85%) is mobilized from nonmitochondrial intracellular stores that are resistant to chelation ofextracellular calcium and are selectively depleted by prior administration of 100 nM ionomycin (5) . This calcium ionophore is preferentially soluble in intracellular membranes as indicated by its ability to cause a cytosolic calcium peak in the face of chelation of extracellular calcium (5) , and independently of changes in phosphatidylinositol metabolism (13) . TRH and ionomycin, at this low concentration, access the same intracellular calcium store in that prior administration of either agent essentially eliminates the peak response to the other (5) . The acute TRH-in-duced spike in [Ca2J]i occurs in association with the phosphodiesteratic hydrolysis of phosphatidylinositol to the protein kinase C-stimulating agent, diacylglycerol (DAG) and inositol trisphosphates (IP3)2 (13) (14) (15) . IP3 is currently believed to be the mediator responsible for releasing Ca2+ from intracellular stores (16) . Subsequent to the nadir of this first phase in elevated [Ca2+],, a second plateau (phase II) of elevated [Ca2+]J occurs within 3 min, and is sustained over a long period (> 30 min) in the continued presence of TRH (4, 5) . This second phase is unaffected by pretreatment of the cells with ionomycin but, unlike phase I, it is eliminated by EGTA, verapamil, or nifedipine, indicating its dependence on influx of extracellular calcium through voltage-sensitive calcium channels (4, 5) .
The experiments presented in this report describe an enhancement of the (Ca2+]i response to TRH receptor activation in cells that were pretreated with 1,25(OH)2D3, and examine the site at which this steroid hormone acts to modulate the response to TRH.
Methods
Cell culture. GH4C1 cells were grown in monolayer culture in Ham's FlO nutrient mixture supplemented with 15% horse serum and 2.5% fetal bovine serum as described previously (17, 18) . Cells were harvested, using Hepes buffered saline solution (HBSS) II buffer (1 18 mM NaCl, 4.6 mM KCl, 10 mM D-glucose, 20 mM Hepes, 400MuM CaCl2, pH 7.2) lacking calcium and containing 0.02% EDTA, 72 h before experimentation and transferred to 100-mm Petri dishes in a hormone-free chemically defined medium containing CaCl2 (0.4 mM) as described previously (9 
Determination ofinositolphosphateformation. Myo-[2-3H(N)]ino-
sitol (8 MCi/I0 ml) was added to the cells as described previously (23) at the time of plating in serum-free medium 72 h before experimentation. Cells were harvested as described above and incubated for 30 min at 37°C before stimulation with 1.5 MM TRH. Treatment was stopped by the addition of ice-cold trichloroacetic acid (TCA) (10% final concentration). The precipitate was removed by centrifugation and the soluble fraction stored at -20°C frozen for up to 1 wk before assay. Etherextracted, water-soluble fractions were separated on a 1 X 2-cm Dowex AG-IXB anion exchange resin using HCI (30-500 mM) as the eluants (24) . Metabolites were quantified by liquid scintillation counting ofthe separated fractions. Validation of this chromatographic method has been obtained by comparison with the elution pattern of authentic
[32P]IP3 (23) .
Materials. Culture media, sera, and reagents (amino acids, vitamins, and salts) used in the chemically defined media (MEM-SS) were obtained from Gibco (Grand Island, NY). Quin2-acetoxymethyl ester (quin2-AM) was purchased from Lancaster Synthesis (Lancashire, England). TRH was a gift from Dr. Eugene Woroch, Abbott Laboratories (North Chicago, IL). Ionomycin was a gift from Dr. Chao-Min Liu, and 1,25-dihydroxyvitamin D3 was from Dr. M. Uskokovic, both from Hoffman-LaRoche (Nutley, NJ). Digitonin was purchased from Fisher (Table I ). This enhanced intracellular cytosolic calcium increase was restricted to the peak phase ofthe TRH response. The sustained plateau phase of the TRH response was not significantly affected (P > 0.05) by pretreatment with 1,25(OH)2D3 for 24 or 48 h (Fig. 2) . TRH-induced plateau to basal ratios of (Ca2+]i were 1.17 and 1.15 in control and 48 h pretreated cells, respectively (Table I) . Acute exposure to 1 nM 1,25(OH)2D3 did not affect
[Ca2+]i, nor did it enhance the response to TRH (Fig. 3) (Fig. 4 B) (27) .
The mechanism or mechanisms underlying the transduction of vitamin D receptor activation to calcium uptake has been the subject of intensive investigation. Although several proteins have been shown to be induced by this hormone, including at least four different (based on molecular weight 
